Context: Thyroglobulin (Tg) levels measured at the time of remnant ablation after thyroid hormone withdrawal (THW) were shown to have prognostic value in predicting disease-free status.
T he prognosis of differentiated thyroid carcinoma (DTC) is very good, with a 10-year survival rate higher than 85% in most series (1) . The initial approach to a patient with DTC usually consists of surgery, followed by radioactive iodine (RAI) remnant ablation. After the initial approach, follow-up of most patients will rely on serum thyroglobulin (Tg) levels and neck ultrasound. Due to its high negative predictive value (NPV) (2), a stimulated Tg measurement is recommended by most Guidelines and Clinical Practice Recommendations 6 to 12 months after ablation (3) (4) (5) . In ablated patients, Tg measurements have high sensitivity (85%-95%) for the detection of residual tumor or nontumor thyroid tissue (6) . Stimulation of Tg secretion can be performed either by withdrawing levothyroxine for 3 to 5 weeks (endogenous TSH stimulation) or by the administration of recombinant human TSH (rhTSH); in the latter, 2 injections are given on consecutive days and Tg is determined on the fifth day.
The measurement of postoperative Tg levels just before RAI treatment was initially called into question, because normal thyroid remnants would contribute to Tg production. Nevertheless, several studies demonstrated the predictive value of Tg levels measured at ablation under endogenous TSH stimulation (7) (8) (9) (10) . A meta-analysis examined the predictive value of endogenously stimulated Tg just before ablative treatment on subsequent diseasefree status (11) ; the authors concluded that preablation Tg level is an economical tool with a high NPV, suggesting that a low preablation Tg (below 10 ng/mL) should be considered a favorable risk factor.
It has been demonstrated that rhTSH is a safe and effective way of preparing patients for RAI remnant ablation. When compared with endogenous stimulation, rhTSH conferred similar rates of success (80%-90%) while avoiding signs and symptoms of hypothyroidism and maintaining quality of life in low-, intermediate-, or high-risk patients (12) (13) (14) (15) . Recent data also demonstrated comparable benefits of RAI therapy for patients with metastatic DTC prepared either with endogenous stimulation or rhTSH (16 -18) ; this issue is still under debate, because previous reports in a limited number of patients raised the possibility of lower RAI uptake from metastatic lesions after rhTSH preparation when compared with thyroid hormone withdrawal (THW) (19, 20) . The long-term outcome of patients ablated under rhTSH stimulation also appears to be similar (21) (22) (23) . Furthermore, the radiation exposure to other organs is decreased on average by 35% (24) . In the preparation for RAI ablation, 131 I should be given on day 3 after 2 injections of rhTSH, because this day corresponds to the TSH peak levels in serum. This timeline disallows a stimulated Tg measurement before RAI administration. Moreover, the early sequential changes in serum Tg after RAI ablation raised concerns about its predictive value when rhTSH is used and Tg is measured after iodine administration (25) . Until now, no clinical studies confirmed or discarded this hypothesis.
The objective of the current study was to examine the predictive value of Tg at the time of ablation for diseasefree status 1 year after RAI therapy, when rhTSH is used. We compared the results with the data of a similar group of patients that underwent ablation under endogenous TSH stimulation.
Patients and Methods
In this study, we included 293 consecutive patients with a DTC and no evidence of distant metastases at diagnosis, followed at our institution between 2006 and 2011. All the patients were submitted to total or near-total thyroidectomy (in one or two stages) without routine central lymph node dissection, followed by RAI remnant ablation after stimulation with rhTSH (n ϭ 151) or endogenous TSH (n ϭ 142). Two surgical teams were involved, each of them with 4 surgeons experienced in thyroid surgery. The assignment of patients to either group was done by simple random allocation, using a computer-generated list (Random Allocation Software version 1.0) with 2 groups. Patients with poorly differentiated thyroid carcinomas were excluded. In the group prepared with rhTSH, RAI ablation consisted in the administration of 3.7 GBq (100 mCi) 131 I on the third day, preceded by 2 injections of 0.9 mg rhTSH performed on consecutive days, in accordance with standard protocols (3). Endogenously stimulated ablation was performed with 3.7 GBq (100 mCi) 131 I after 4 weeks of THW. A low-iodine diet was recommended in the week preceding RAI treatment. When rhTSH was used, Tg and Tg antibodies (Tg-Abs) at the time of ablation were measured on the fifth day after the first rhTSH injection, corresponding to day 3 after RAI. In the THW group, Tg and Tg-Abs were measured immediately before RAI administration. A wholebody scintigraphy (WBS) was performed 5 to 7 days after the therapeutic activity had been administered in all the patients. Whenever there was suspicion of RAI uptake outside the thyroid bed, single-photon emission computed tomography fusion imaging (SPECT/CT) was used to clarify the region of uptake. The follow-up protocol included neck ultrasound and measurement of TSH, free T 4 (fT 4 ), Tg, and Tg-Abs while on suppressive L-T 4 treatment 3 months after RAI ablation. Approximately 1 year (9 -12 months) after ablation, neck ultrasound was repeated and an rhTSH-stimulated Tg level was obtained, together with TgAbs. Patients were consider as being disease-free at 1 year if they had a normal neck ultrasound, a stimulated Tg below 1 ng/mL, and no RAI uptake outside the thyroid bed in post-therapy WBS. All the patients demonstrating positive Tg-Abs at any time during follow-up were excluded.
Adding to the factors previously mentioned, the following data were registered: age at diagnosis, gender, histology, and American Joint Cancer Committee (AJCC)/Union Internationale Contre le Cancer (UICC) TNM staging (sixth edition). In accordance with 2009 American Thyroid Association Guidelines (3), we defined a group of patients harboring tumors with aggressive histology if any of the following features was present: tall cell variant, solid variant, columnar cell variant, or vascular invasion.
We also took into consideration other factors known to have prognostic significance, including age of the patient (Ͻ45 vs Ն45 years old), gender, tumor staging, aggressive histology as previously defined, and presence of lymph node metastases at diagnosis.
Patients with tumors pT1-T2, N0 -Nx and no aggressive histology were considered as low-risk, whereas patients harboring tumors T3-T4, N1 or aggressive histology were considered as intermediate-to high-risk.
Patients signed an informed consent form for the study, which was approved by the Internal Reviewing Board.
Serum Tg, TSH, and fT 4 measurement
The Tg was measured using fully automated chemiluminescence assay (IMMULITE 2000; DPC, Buhlmann), with analytical sensitivity of 0.2 ng/mL and functional sensitivity of 0.9 ng/mL. Third-generation Tg-Abs determination was also performed with chemiluminescence assay, with analytical sensitivity of 10 IU/mL and reference value Ͻ40 IU/mL (IMMULITE 2000) . The presence of Tg-Abs above the reference value was used as criteria for exclusion.
TSH and fT 4 were assayed by chemiluminescence (IMMULITE 2000), with a reference range of 0.4 to 4.0 IU/mL for TSH and 0.8 to 1.9 ng/dL for fT 4 .
Imaging
Post-therapeutic WBS was performed 5 to 7 days after RAI administration, using a dual-head ␥-camera (Discovery VH; General Electric). The same equipment allowed single-photon emission computed tomography (SPECT/CT) fusion imaging when required. For quantitative measurement of RAI uptake, we used Molsgaard Medical ␥-analyzer type 1600 from 2007 until 2010; afterward, this equipment was replaced by the Capintec Captus 3000 Thyroid Uptake System.
Neck ultrasound was performed with a linear, multifrequency 7.5-to 10.0-Mhz transducer.
Statistics
All statistical analysis was performed using SPSS version 20.0 (SPSS Inc). Descriptive statistics are presented as numbers of patients and percentages or mean Ϯ SD. variate and a multivariate logistic regression model (enter method, all the variables were entered in the model in one single step). All variables significantly associated with disease-free status at 1 year were included in the multivariate analysis. Statistical significance was defined by a P value Ͻ.05.
Results

Group ablated after rhTSH stimulation
A total of 151 patients were initially selected for inclusion, and 19 patients were excluded due to positive Tg-Abs during follow-up; 1 patient was excluded because of missing data.
The clinical data and tumor characteristics of the group (n ϭ 131) are summarized in Table 1 . A 1-stage surgical procedure was performed in 88 patients (67.2%), and 43 (32.8%) were treated in 2 surgical stages.
Mean age at the time of surgery was 47.2 Ϯ 15.0 years. Mean follow-up time after RAI ablation was 24.3 Ϯ 9.3 months.
A total of 96 patients (73.3%) were considered as being free of disease 1 year after RAI ablation. In the group with persistent or recurrent disease (n ϭ 35), 27 (77.1%) displayed elevated Tg levels, 17 (48.6%) had an abnormal neck ultrasound, and 17 (48.6%) presented RAI uptake outside the thyroid bed. From the clinical standpoint, these results corresponded to the presence of proven lymph node metastases in 16 patients (45.7%) who were submitted to fine-needle aspiration cytology with Tg measurement in washout fluid and subsequent surgical resection (2 were considered as N1a and 14 as N1b). Distant metastases to the lung or bone were present in 9 patients (25.7%), and 3 patients (8.6%) presented with local recurrences in the thyroid bed. Nine patients had isolated elevation of stimulated Tg levels at 1 year without further evidence of disease.
Predictive value of Tg at rhTSH-aided ablation
Tg levels at ablation ranged from 0 to 1927 ng/mL, with values significantly higher in the group of patients with persistent or recurrent disease (136.3 Ϯ 341.0 vs 17.9 Ϯ 49.1 ng/mL; P Ͻ .001).
Undetectable Tg was found in 13 patients. At 1 year, one of them presented with recurrent disease.
Tg levels at ablation were not significantly different between patients submitted to a 1-stage or 2-stage surgical procedure (52.5 Ϯ 214.9 vs 41.6 Ϯ 102.7 ng/mL; P ϭ .75).
Before rhTSH administration, the range of TSH levels was 0.01 to 3.7 U/mL. All the patients had fT 4 and fT 3 within the reference range.
ROC curve (Figure 1 ) analysis demonstrated that stimulated Tg at ablation using rhTSH was predictive of disease persistence 1 year later (area under the curve ϭ 0.79, SE ϭ 0.05, P Ͻ .001). A cutoff value of Tg level was established at 7.2 ng/mL, with a sensitivity of 80.0%, specificity of 62.5%, PPV of 43.8%, and NPV of 89.6%. This cutoff value was valid for both low-risk patients (NPV ϭ 89.2%) and intermediate-to high-risk patients (NPV ϭ 90.0%) (Supplemental Data, published on The Endocrine Society's Journals Online website at http://jcem.endojournals.org).
The presence of initial lymph node metastasis (P Ͻ .001), aggressive histology (P ϭ .03), and higher stage (P ϭ .001) were significantly associated with persistent or recurrent disease 1 year later (Table 1) .
In multivariate analysis, Tg at ablation appeared as an independent prognostic marker at 1 year, irrespective of the presence of initial lymph node metastases (also an independent prognostic marker), aggressive histology, and higher stage (Table 2) .
Group ablated after THW
We performed a similar analysis in the group of 142 patients submitted to RAI ablation after THW. Tg-Abs were present in 17 patients that were excluded from the analysis. Two patients were excluded due to missing data.
The characteristics of the included population (n ϭ 123) are shown in Table 3 . A 1-stage surgical procedure was performed in 90 patients (73.2%), and 33 (26.8%) were treated in 2 surgical stages. A total of 95 patients (77.2%) were considered as being disease-free 1 year after ablation. In the group with persistent or recurrent disease (n ϭ 28), 25 (89.3%) displayed elevated Tg levels, 16 (57.1%) had an abnormal neck ultrasound, and 11 (39.3%) showed RAI uptake outside the thyroid bed. This corresponded to the presence of proven lymph node metastases in 11 patients (39.3%) (3 were considered as N1a and 8 as N1b); distant metastases (lung or bone) were present in 7 patients (25.0%). Recurrences in the thyroid bed occurred in 2 patients (7.1%). Ten patients had high levels of stimulated Tg at 1 year without further evidence of disease.
Predictive value of Tg at ablation under endogenous TSH stimulation
Tg levels at ablation ranged from 0 to 691 ng/mL, with values significantly higher in the group of patients with persistent or recurrent disease at 1 year (123.6 Ϯ 166.6 vs 7.7 Ϯ 36.2 ng/mL; P Ͻ .001).
An undetectable Tg was found in 16 patients. At 1 year, all of them were free of disease.
All patients were hypothyroid before RAI administration, with TSH levels Ͼ30 U/mL (mean ϭ 89.2 Ϯ 39.4 U/mL; range ϭ 31-243 U/mL). We found no correlation between TSH and Tg levels (r ϭ 0.16; P ϭ .09).
Tg levels at ablation were not significantly different between patients submitted to a 1-stage or 2-stage surgical procedure (35.3 Ϯ 101.3 vs 30.6 Ϯ 88.2 ng/mL; P ϭ .81).
In the THW group, Tg measurement at ablation was able to predict the presence of persistent or recurrent disease (area under the curve ϭ 0.93; SE ϭ 0.3 P Ͻ .001) (Figure 2) . When a cutoff value of 7.2 ng/mL was applied, we obtained a sensitivity of 85.7%, a specificity of 83.2%, a PPV of 60.0%, and an NPV of 95.2%. The same cutoff was appropriate for both low-risk (NPV ϭ 95.8%) and intermediate-to high-risk patients (NPV ϭ 91.7%) (Supplemental data).
The presence of lymph node metastasis (P Ͻ .001) and an aggressive histology variant (P ϭ .01) were also predictive of disease persistence 1 year later. Only Tg levels and lymph node metastasis were independent predictors of tumor persistence or recurrence 1 year later (Table 4) .
Discussion
The follow-up of patients with DTC relies on serum Tg measurements as an important modality for identifying patients with persistent or recurrent disease, particularly when total or near-total thyroidectomy followed by RAI remnant ablation has been performed. Tests with high NPV are particularly useful in the follow-up of patients with DTC, because they allow the identification of the vast majority of patients unlikely to experience disease recurrence. The definition of diseasefree 8 to 12 months after ablation implies an undetectable stimulated serum Tg together with a normal neck ultrasound, provided that there was no uptake outside the thyroid bed in post-treatment WBS (3, 4) . This is based on the high NPV of stimulated Tg levels at this time: patients with an undetectable Tg have a 95% to 99.5% likelihood of being completely free of tumor on longterm follow-up (9, 26). In recent years, several studies assessed the predictive value of serum Tg measured at the time of remnant ablation (7-9, 27-33), after THW. Although there was a wide range of values for sensitivity (47.1%-94.9%), specificity (54.1%-94.1%), and PPV (26.0%-75.0%) among different studies, the NPV showed a much narrower variation (81.6%-99.2%). A meta-analysis involving nearly 4000 patients confirmed that preablation Tg levels can be a useful negative predictor of persistent or recurrent DTC (11) . The authors defined a cutoff of 10 ng/mL for optimal sensitivity and specificity. About 70% of patients had Tg levels below this threshold, and the overall NPV was 94.2%.
In this study, we evaluated the predictive value of Tg at the time of rhTSH-aided ablation. Our results show that Tg at ablation was an independent predictor of disease persistence or recurrence 1 year later. Based on the ROC curve analysis, we defined a Tg cutoff of 7.2 ng/mL as being the most adequate for optimal sensitivity and specificity. A patient with a Tg below this threshold had a likelihood of about 10% of having persistent disease 1 year later, and this holds true whether the patient was considered low-or intermediate-to high-risk. For comparison, we performed the same analysis in a clinically similar group of patients ablated after L-T 4 withdrawal. Using the same cutoff, a patient with endogenously stimulated Tg below 7.2 ng/mL had a 5% likelihood of having persistent or recurrent disease.
Although the follow-up time of this study is relatively short, stimulated Tg at rhTSH-aided ablation was able to predict a disease-free status at a critical time during the follow-up of patients with DTC (9, 26) . This simple determination has the potential to be used by clinicians as a tool in dynamic risk stratification of the patients and, combined with other factors known to have prognostic implications, may be useful in forecasting a good outcome. In clinical practice, stimulated Tg at ablation may help physicians in establishing the optimal TSH level for the individual patient. Initial TSH suppression (Ͻ0.1 mU/L) is recommended for intermediate-and high-risk patients, whereas a TSH at or below the lower limit of the reference range is recommended for low-risk patients (3) . Adverse effects of TSH suppression include the known consequences of subclinical thyrotoxicosis, namely exacerbations of ischemic heart disease and atrial fibrillation. Patients with relevant cardiovascular disease are ideal candidates for rhTSH-aided ablation, because a period of hypothyroidism may also deteriorate their health status. The knowledge of the NPV of stimulated Tg at rhTSHaided ablation may cause the physician to refrain from TSH suppression, an approach that can have important iatrogenic effects in patients with cardiovascular disease. The predictive value of Tg at rhTSH-aided ablation seems also valid for intermediate-to high-risk patients. This can be helpful in the follow-up strategy of these patients, as less consensus and fewer guidelines are available. A simple test with high NPV has the potential to decrease the frequency of repeated stimulated Tg measurements and neck ultrasounds. Further studies will be necessary to specifically address the aforementioned issues.
When rhTSH is used in the preparation for remnant ablation, Tg is measured in the fifth day after the first injection, 48 hours after RAI administration. A previous study raised concerns about the significance of serum Tg levels whenever rhTSH is used (25) . Taïeb et al (25) evaluated the sequential changes in serum Tg after RAI ablation in 26 consecutive hypothyroid patients: Tg levels increased during the next 48 hours after 131 I administration due to thyroid cell damage; furthermore, serum Tg levels measured at 48 hours were not correlated with baseline Tg levels. These data raised the question of whether or not rhTSH-stimulated Tg at ablation could be used as a predictive tool. Our study demonstrates that rhTSH-stimulated serum Tg has predictive value for disease persistence or recurrence 1 year later, in a sample of 131 patients, using a follow-up protocol in accordance with both European and American guidelines. Furthermore, when we compare the results obtained with rhTSH-stimulated and the cohort of patients prepared with THW, the NPV of the test was only slightly higher (89.6% vs 95.2%).
It is well known that TSH levels are a fundamental determinant of Tg levels in the follow-up of patients with DTC. In this study, we found no correlation between TSH and Tg in the THW group. In this setting and as long as there is appropriate stimulation (TSH Ͼ 30 U/mL), it seems that TSH is not a major determinant of Tg levels. A similar analysis is not presented for the rhTSH-aided ablation group, as blood was not collected in the third day (peak TSH) after the first rhTSH injection but only in the fifth day, precluding an accurate investigation of the relationship between peak TSH and Tg levels.
The cutoff value defined in this study is close to the threshold established in most studies performed in hypothyroid conditions. In fact, if the cutoff suggested by Webb et al (11) was used (10 ng/mL) in our series, the NPV would be 89.3% for rhTSH-stimulated Tg and 94.4% for endogenously stimulated Tg (data not shown). When Tg measurement is used for tumor detection in the follow-up of patients with DTC, the stimulated levels were reported to be lower if rhTSH is used in comparison with THW (34) . At variance with hypothyroidism, rhTSH-aided ablation requires a Tg test after RAI administration. This can contribute to elevated Tg levels, through RAI-induced cellular damage, in rhTSH-stimulated patients. Although a comparison between absolute stimulated Tg levels per-formed under different conditions should be made with caution due to the reasons mentioned above, similar cutoff values for the prediction of absence of disease at ablation were found in this cohort.
A study by Giovanella et al (35) evaluated the predictive value of Tg measurement before rhTSH-aided ablative therapy for detecting metastases. Serum Tg was determined while the patients were under T 4 treatment and a highly sensitive Tg assay was used (functional sensitivity ϭ 0.2 ng/mL). The cutoff level for persistent/recurrent disease derived from the ROC curve was 0.65 ng/mL. This study raised the possibility of using postsurgery basal Tg levels determined by a second-generation assay as a predictive tool. Unfortunately, this methodology is not widely available. The fact that most patients were submitted to total thyroidectomy with lymph node dissection in the central compartment may also contribute to the good results obtained with the aforementioned test.
There is controversy about the risk-benefit ratio of prophylactic central compartment node dissection. The procedure allows a more precise staging (36) and may decrease regional recurrence and mortality (37) . On the other hand, other studies demonstrated higher morbidity with no reduction in the recurrence rates (38, 39) . The absence of routine central lymph node dissection in our hospital may implicate a less precise staging of the patients and may contribute for the relatively high number of local recurrences. In this situation, rhTSH-stimulated Tg at ablation may play an important role as an independent predictive evaluator. Further evidence is required concerning the putative value of rhTSH-stimulated Tg at ablation as a way of predicting disease-free status when prophylactic central-compartment neck dissection is performed.
In conclusion, our results demonstrate that when rhTSH is used, stimulated Tg at ablation may be used as a prognostic marker, allowing the definition of a group of patients with a high probability of being disease-free 1 year after ablation. Based on our data, we recommend an institutional cutoff value similar to the one established for Tg at ablation after THW.
